Specifically for the DUT + TAM FDC vs. tamsulosin monotherapy, economic analyses have been conducted in the UK, [10] Canada, [11] Spain, [12] and Scandinavia, [13] where the fixed-dose ...

Tamsulosin is currently the only third-generation uroselective α 1A-adrenergic antagonist commercially available in the United States. Pharmacologic studies have found that tamsulosin has a 40-fo ...

Lower urinary tract symptoms and overactive bladder are commonly treated with antimuscarinic agents or α-receptor antagonists. Kaplan et al. investigated the efficacy and safety of the ...

These vascular effects can, however, be greatly reduced by the use of the α 1a receptor antagonist tamsulosin, which specifically targets urothelial smooth muscle. α-Blockers are not yet ...